background image

Small Cell Lung Cancer Clinical Trials

Find clinical trials for small cell lung cancer. Search for small cell lung cancer clinical trials in different cities and states across the United States.

Filter
1
Active & Responsive

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: 11 recruiting locations
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase1, Phase2, Recruiting
Active & Responsive

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

for
Metastatic Non Small Cell Lung Cancer
Location: 32 recruiting locations
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT05555732

Phase3, Recruiting
Active & Responsive

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

for
Solid Tumors, Gastric Cancer,
Location: 6 recruiting locations
Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All

Age: 18+

Code: NCT06710132

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: 8 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase1, Phase2, Recruiting
Active & Responsive

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

for
Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Location: 1 recruiting location
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT05800587

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: 6 recruiting locations
Sponsor: Phanes Therapeutics

Sex: All

Age: 18+

Code: NCT05431270

Phase1, Phase2, Recruiting
Active & Responsive

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT05787587

Phase1, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: 13 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

for
Non-Small Cell Lung Cancer, NSCLC,
Location: 8 recruiting locations
Sponsor: Antares Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06043817

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

for
High-grade Serous Ovarian Carcinoma (HGSOC),
Location: 5 recruiting locations
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06476808

Phase1, Recruiting